Literature DB >> 9500623

Orthotopic liver transplantation in high-risk patients: risk factors associated with mortality and infectious morbidity.

T Gayowski1, I R Marino, N Singh, H Doyle, M Wagener, J J Fung, T E Starzl.   

Abstract

BACKGROUND: One of the most controversial areas in patient selection and donor allocation is the high-risk patient. Risk factors for mortality and major infectious morbidity were prospectively analyzed in consecutive United States veterans undergoing liver transplantation under primary tacrolimus-based immunosuppression.
METHODS: Twenty-eight pre-liver transplant, operative, and posttransplant risk factors were examined univariately and multivariately in 140 consecutive liver transplants in 130 veterans (98% male; mean age, 47.3 years).
RESULTS: Eighty-two percent of the patients had postnecrotic cirrhosis due to viral hepatitis or ethanol (20% ethanol alone), and only 12% had cholestatic liver disease. Ninety-eight percent of the patients were hospitalized at the time of transplantation (66% United Network for Organ Sharing [UNOS] 2, 32% UNOS 1). Major bacterial infection, posttransplant dialysis, additional immunosuppression, readmission to intensive care unit (P=0.0001 for all), major fungal infection, posttransplant abdominal surgery, posttransplant intensive care unit stay length of stay (P<0.005 for all), donor age, pretransplant dialysis, and creatinine (P<0.05 for all) were significantly associated with mortality by univariate analysis. Underlying liver disease, cytomegalovirus infection and disease, portal vein thrombosis, UNOS status, Childs-Pugh score, patient age, pretransplant bilirubin, ischemia time, and operative blood loss were not significant predictors of mortality. Patients with hepatitis C (HCV) and recurrent HCV had a trend towards higher mortality (P=0.18). By multivariate analysis, donor age, any major infection, additional immunosuppression, posttransplant dialysis, and subsequent transplantation were significant independent predictors of mortality (P<0.05). Major infectious morbidity was associated with HCV recurrence (P=0.003), posttransplant dialysis (P=0.0001), pretransplant creatinine, donor age, median blood loss, intensive care unit length of stay, additional immunosuppression, and biopsy-proven rejection (P<0.05 for all). By multivariate analysis, intensive care unit length of stay and additional immunosuppression were significant independent predictors of infectious morbidity (P<0.03). HCV recurrence was of borderline significance (P=0.07).
CONCLUSIONS: Biologic and physiologic parameters appear to be more powerful predictors of mortality and morbidity after liver transplantation. Both donor and recipient variables need to be considered for early and late outcome analysis and risk assessment modeling.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9500623      PMCID: PMC2972634          DOI: 10.1097/00007890-199802270-00008

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  23 in total

1.  The high-risk liver allograft recipient. Should allocation policy consider outcome?

Authors:  F L Delmonico; R L Jenkins; R Freeman; J Vacanti; J Bradley; J L Dienstag; C Trey; W D Lewis; C W Lillehei; H Auchincloss
Journal:  Arch Surg       Date:  1992-05

2.  Assessing risk in liver transplantation. Special reference to the significance of a positive cytotoxic crossmatch.

Authors:  H R Doyle; I R Marino; F Morelli; C Doria; L Aldrighetti; J McMichael; J Martell; T Gayowski; T E Starzl
Journal:  Ann Surg       Date:  1996-08       Impact factor: 12.969

3.  Immunoregulatory cytokines in chronic hepatitis C virus infection: pre- and posttreatment with interferon alfa.

Authors:  T V Cacciarelli; O M Martinez; R G Gish; J C Villanueva; S M Krams
Journal:  Hepatology       Date:  1996-07       Impact factor: 17.425

4.  Preoperative assessment of risk in liver transplantation: a multivariate analysis in 2376 cases of the UW era.

Authors:  I R Marino; F Morelli; C Doria; T Gayowski; J McMichael; J J Fung; T E Starzl; H R Doyle
Journal:  Transplant Proc       Date:  1997 Feb-Mar       Impact factor: 1.066

5.  Prioritization and organ distribution for liver transplantation.

Authors:  O Bronsther; J J Fung; A Izakis; D Van Thiel; T E Starzl
Journal:  JAMA       Date:  1994-01-12       Impact factor: 56.272

6.  Liver transplant candidate stratification systems. Implications for third-party payors and organ allocation.

Authors:  P Muto; R B Freeman; C E Haug; A Lu; R J Rohrer
Journal:  Transplantation       Date:  1994-01       Impact factor: 4.939

7.  Outcome of patients with renal insufficiency undergoing liver or liver-kidney transplantation.

Authors:  R S Brown; M Lombardero; J R Lake
Journal:  Transplantation       Date:  1996-12-27       Impact factor: 4.939

8.  There is an answer to the shortage of organ donors.

Authors:  R N Garrison; F R Bentley; G H Raque; H C Polk; L C Sladek; M J Evanisko; B A Lucas
Journal:  Surg Gynecol Obstet       Date:  1991-11

9.  Positive pretransplant crossmatches predict early graft loss in liver allograft recipients.

Authors:  S M Katz; P M Kimball; C Ozaki; H Monsour; J Clark; D Cavazos; B D Kahan; R P Wood; R H Kerman
Journal:  Transplantation       Date:  1994-02-27       Impact factor: 4.939

10.  Preoperative risk factor assessment in liver transplantation.

Authors:  P Baliga; R M Merion; J G Turcotte; J M Ham; K S Henley; M R Lucey; A Schork; Y Shyr; D A Campbell
Journal:  Surgery       Date:  1992-10       Impact factor: 3.982

View more
  5 in total

Review 1.  Cardiohepatic syndrome.

Authors:  Gerhard Poelzl; Johann Auer
Journal:  Curr Heart Fail Rep       Date:  2015-02

2.  Immunotherapy with tacrolimus (FK506) does not select for resistance to calcineurin inhibitors in Candida albicans isolates from liver transplant patients.

Authors:  Jennifer L Reedy; Shahid Husain; Michael Ison; Timothy L Pruett; Nina Singh; Joseph Heitman
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

3.  Multidisciplinary approach to cardiac and pulmonary vascular disease risk assessment in liver transplantation: An evaluation of the evidence and consensus recommendations.

Authors:  Lisa B VanWagner; Matthew E Harinstein; James R Runo; Christopher Darling; Marina Serper; Shelley Hall; Jon A Kobashigawa; Laura L Hammel
Journal:  Am J Transplant       Date:  2017-11-18       Impact factor: 8.086

Review 4.  Cirrhotic cardiomyopathy.

Authors:  Soon Koo Baik; Tamer R Fouad; Samuel S Lee
Journal:  Orphanet J Rare Dis       Date:  2007-03-27       Impact factor: 4.123

Review 5.  Septic shock after liver transplantation successfully treated with endotoxin and cytokine adsorption continuous renal replacement therapy: a case report and literature review.

Authors:  Yining Li; Linshan Zhou; Lingzhi Yang; Fang Yuan
Journal:  J Int Med Res       Date:  2020-07       Impact factor: 1.671

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.